ETD 002
Alternative Names: ETD-002; GDC-6988; RG-6421Latest Information Update: 06 Dec 2024
At a glance
- Originator Enterprise Therapeutics
- Class Antiasthmatics; Antifibrotics
- Mechanism of Action Chloride channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Bronchiectasis; Chronic obstructive pulmonary disease
- Phase I Cystic fibrosis
Most Recent Events
- 18 Nov 2024 Phase-I/II clinical trials in Bronchiectasis in USA (Inhalation) (NCT06603246)
- 18 Nov 2024 Phase-I/II clinical trials in Chronic obstructive pulmonary disease in USA (Inhalation) (NCT06603246)
- 01 Oct 2024 Genentech plans a phase I trial for Bronchiectasis and Chronic Obstructive Pulmonary Disease in October 2024 (Inhalation, Powder) (NCT06603246)